Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of BEBT-503 in Healthy Subjects
NCT05391880Phase 1Completed
- Sponsor
- BeBetter Med
- Start
- Aug 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM), Nonalcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) comparing BEBT-503 with Placebo (2 arms). Primary endpoints: Single dose safety at Day 10 and Multiple dose safety at Day 18. Started Aug 2022; status: completed.
02
Drugs
bebt-503
03
Conditions
type 2 diabetes mellitus (T2DM)Nonalcoholic steatohepatitis (NASH)non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT05391880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05391880.